Vitamin D Status and COVID-19 Clinical Outcomes in Hospitalized Patients
Endocrine Research · 03.04.2021 · 46 (2) · 66-73
DOI: 10.1080/07435800.2020.1867162 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine Research, online erschienen am 30.12.2020. Verfasst von Betsy Szeto und 6 weiteren Autor:innen. Beteiligte Einrichtung: Columbia University Vagelos College of Physicians and Surgeons, New York, USA. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Context
Populations severely affected by COVID-19 are also at risk for vitamin D deficiency. Common risk factors include older age, chronic illness, obesity, and non-Caucasian race. Vitamin D deficiency has been associated with risk for respiratory infections and failure, susceptibility and response to therapy for enveloped virus infection, and immune-mediated inflammatory reaction.
Objective
To test the hypothesis that 25-hydroxyvitamin D[25(OH)D] deficiency is a risk factor for severity of COVID-19 respiratory and inflammatory complications.
Design
We examined the relationship between prehospitalization 25(OH)D levels (obtained 1-365 days prior to admission) and COVID-19 clinical outcomes in 700 COVID-19 positive hospitalized patients.Primary Outcomes: Discharge status, mortality, length of stay, intubation status, renal replacement.Secondary Outcomes: Inflammatory markers.
Results
25(OH)D levels were available in 93 patients [25(OH)D:25(IQR:17-33)ng/mL]. Compared to those without 25(OH)D levels, those with measurements did not differ in age, BMI or distribution of sex and race, but were more likely to have comorbidities. Those with 25(OH)D < 20 ng/mL (n = 35) did not differ from those with 25(OH)D ≥ 20 ng/mL in terms of age, sex, race, BMI, or comorbidities. Low 25(OH)D tended to be associated with younger age and lower frequency of preexisting pulmonary disease. There were no significant between-group differences in any outcome. Results were similar in those ≥50 years, in male/female-only cohorts, and when differing 25(OH)D thresholds were used (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Columbia University Vagelos College of Physicians and Surgeons, New York, USA.
- Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, USA.
Zitieren
APA
Szeto, B., Zucker, J. E., LaSota, E. D., Rubin, M. R., Walker, M. D., Yin, M. T., & Cohen, A. (2021). Vitamin D Status and COVID-19 Clinical Outcomes in Hospitalized Patients. Endocrine Research, 46(2), 66-73. https://doi.org/10.1080/07435800.2020.1867162
Vancouver
Szeto B, Zucker JE, LaSota ED, Rubin MR, Walker MD, Yin MT, et al. Vitamin D Status and COVID-19 Clinical Outcomes in Hospitalized Patients. Endocrine Research. 2021;46(2):66-73. doi:10.1080/07435800.2020.1867162
BibTeX
@article{Szeto2021,
author = {Szeto, Betsy and Zucker, Jason E and LaSota, Elijah D and Rubin, Mishaela R and Walker, Marcella D and Yin, Michael T and Cohen, Adi},
title = {Vitamin D Status and COVID-19 Clinical Outcomes in Hospitalized Patients},
journal = {Endocrine Research},
year = {2021},
volume = {46},
number = {2},
pages = {66--73},
doi = {10.1080/07435800.2020.1867162}
}
EUVIMED